PASADENA, Calif., Jan. 10, 2022 /PRNewswire/ -- Alexandria
Venture Investments, the strategic venture capital platform of
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office
REIT and the first, longest-tenured and pioneering owner, operator
and developer uniquely focused on collaborative life science,
agtech and technology campuses in AAA innovation cluster locations,
today announced that it was recognized by Silicon Valley Bank in
its "Healthcare Investments and Exits: Annual 2022 Report" as the
#1 most active corporate investor in biopharma by new deal volume
(2020–2021) for the fifth consecutive year. This continued and
important recognition is a testament to Alexandria's leadership in and highly
impactful collaboration across the vital life science industry
advancing transformative new modalities and platforms to
meaningfully improve human health and reduce healthcare costs.
Since its inception in 1996, Alexandria Venture Investments has
strategically invested in disruptive life science, agrifoodtech,
climate change and technology companies. Alexandria's robust venture activity is an
integral component of the company's unique and multifaceted
business and provides valuable insight into key industry and
innovation trends; builds and strengthens its relationships with
leading entrepreneurs and investors; and further bolsters its
high-quality roster of over 800 innovative tenants.
"We are extremely proud to continue to be at the vanguard and
heart of the life science industry, which delivered lifesaving
COVID-19 testing, vaccines and therapies in record time and now
continues to leverage its innovative platforms to expand the tool
kit for the ongoing fight against infectious diseases," said
Joel S. Marcus, executive chairman
and founder of Alexandria Real Estate Equities, Inc. and founder
and head of Alexandria Venture Investments. "With over 10,000
diseases known to humankind and less than 10% currently addressable
with therapies, our tenants and venture investment companies are
working tirelessly to successfully meet this massive unmet medical
need. This critical innovation is also the most effective way to
reduce and manage healthcare costs in our country. We are in the
early days of the golden age of biology, accelerated by an exciting
convergence of biology and technology, and we are more committed
than ever to partnering with trailblazing companies poised to
dramatically enhance the future of human health."
Alexandria Venture Investments has a decades-long track record
of investing in dynamic companies that develop life-changing and
lifesaving medicines while it also generates strong and consistent
financial returns. As of December 31,
2021, the platform's deep track record has enabled
Alexandria Venture Investments to generate realized and unrealized
returns in excess of 10x for numerous portfolio companies that are
working across infectious diseases, neuroscience, oncology and
next-generation medicines platforms. Building on this historical
success, Alexandria continues to
invest in impactful companies that are advancing discoveries across
a range of key areas, including infectious diseases and
neuroscience, as well as groundbreaking platforms with immense
potential to address a wide range of diseases.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P
500® urban office REIT, is the first, longest-tenured
and pioneering owner, operator and developer uniquely focused on
collaborative life science, agtech and technology campuses in AAA
innovation cluster locations, with a total market capitalization of
$38.6 billion as of September 30,
2021, and an asset base in North America of 63.9 million SF. The
asset base in North America
includes 38.7 million RSF of operating properties and 4.3 million
RSF of Class A properties undergoing construction, 8.9 million RSF
of near-term and intermediate-term development and redevelopment
projects and 12.0 million SF of future development projects.
Founded in 1994, Alexandria
pioneered this niche and has since established a significant market
presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San
Diego, Seattle,
Maryland and Research Triangle.
Alexandria has a longstanding and
proven track record of developing Class A properties clustered in
urban life science, agtech and technology campuses that provide our
innovative tenants with highly dynamic and collaborative
environments that enhance their ability to successfully recruit and
retain world-class talent and inspire productivity, efficiency,
creativity and success. Alexandria
also provides strategic capital to transformative life science,
agtech and technology companies through our venture capital
platform. We believe our unique business model and diligent
underwriting ensure a high-quality and diverse tenant base that
results in higher occupancy levels, longer lease terms, higher
rental income, higher returns and greater long-term asset value.
For additional information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements include, without
limitation, statements regarding the likelihood of continued
investment activity by the Alexandria Venture Investments platform
and the potential impacts of such investments on Alexandria's business, the companies in which
it invests, current and future healthcare challenges, healthcare
costs and the broader life science, agrifoodtech, climate change
and technology industries. These forward-looking statements are
based on the Company's present intent, beliefs or expectations, but
forward-looking statements are not guaranteed to occur and may not
occur. Actual results may differ materially from those contained in
or implied by the Company's forward-looking statements as a result
of a variety of factors, including, without limitation, the risks
and uncertainties detailed in its filings with the Securities and
Exchange Commission. All forward-looking statements are made as of
the date of this press release, and the Company assumes no
obligation to update this information. For more discussion relating
to risks and uncertainties that could cause actual results to
differ materially from those anticipated in the Company's
forward-looking statements, and risks and uncertainties to the
Company's business in general, please refer to the Company's
filings with the Securities and Exchange Commission, including its
most recent annual report on Form 10-K and any subsequently filed
quarterly reports on Form 10-Q.
CONTACT: Sara
Kabakoff, Vice President – Communications,
(626) 788–5578, skabakoff@are.com
View original
content:https://www.prnewswire.com/news-releases/alexandria-venture-investments-achieves-fifth-consecutive-annual-1-most-active-corporate-investor-in-biopharma-301457614.html
SOURCE Alexandria Real Estate Equities, Inc.